Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus (T2DM).Antidiabetic agents, sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) havedemonstrated cardiovascular benefits, though direct comparative data are limited. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.